ArticleBiochemia medica2025
Routine data analysis for moderate hemolysis interference correction in neuron specific enolase quantification.
Article in Biochemia medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnostic value of pleural fluid neuron-specific enolase for malignant pleural effusion.Journal of thoracic disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Serum neuron specific enolase (NSE) is used as neuroendocrine tumor and central nervous system damage marker. It is present in variable concentrations in erythrocytes and hemolysis interferes in serum NSE quantification. Our aim was to develop a correction formula for moderate hemolysis, based on repeated patient samples instead of artificial sample doping with hemolysates. Materials and methods: We searched in laboratory informatics system for patients with sample pairs obtained within 24 h, for NSE quantification. We registered NSE and hemolytic index (NSE1 and HI1) from the first moderate hemolyzed sample (HI: 15-80), and from the second non-hemolyzed sample obtained afterwards (NSE2 and HI2). In a development cohort (N = 41), we obtained the formula NSE Results: Concentrations of NSE2 differed from NSE1 (P = < 0.001) but not from NSE Conclusions: In summary, with this innovative approach, the NSE
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.